Data from 2 prospective cohort studies showed that chondrocalcinosis was significantly associated with increased odds of incident radiographic knee OA.

Cumulative influenza-associated hospitalization rates during the 2024 to 2025 season were higher than all end-of-season rates from the 2010 to 2011 season onward.

Skin autofluorescence measured advanced glycation end product, which was associated with impaired bone health among patients with type 1 diabetes.

Use of a digital intervention led to clinically significant reductions in psychological distress at 3 months among patients with IRDs.

Complete, but not partial, remission was associated with a lower likelihood of doubling of serum creatinine in patients with pure membranous lupus nephritis.

Greater improvements in disability and pain intensity were seen at 6 and 12 months with acupuncture vs usual care among patients with CLBP.

Polypharmacy among patients with early RA was associated with lower rates of remission and an increased risk for SAEs over a 10-year period.

Rates of alcohol-induced deaths in the United States increased by 89% from 1999 to 2024, most notably among women aged 25 to 34 years.

Topline data were announced from a phase 3 trial evaluating garetosmab in adults with fibrodysplasia ossificans progressiva.

Willingness to prescribe estrogen therapy for patients with a history of gynecologic cancer varied by specialty, experience, and sex.

Anifrolumab, a type I interferon receptor antagonist, is currently approved under the brand name Saphnelo for IV administration in the treatment of moderate to severe SLE.

Tirzepatide and semaglutide had a 64% and 34% probability of being cost-effective at a $100,000 per QALY threshold, respectively.